ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations 26 Jul 2019 The ICR responds to the approval by NHS regulators NICE for the use of targeted cancer drug olaparib earlier in the course of treatment for women with late-stage ovarian cancer and other gynaecological cancers who have BRCA gene mutations. Find out more Show/Hide
Targeted breast cancer drug – olaparib – given green light by EU 16 Apr 2019 European Medicines Agency approves olaparib for women with BRCA-mutant breast cancer – 15 months after licensing in the US. Find out more Show/Hide
New cancer drugs taking longer to reach NHS patients 04 Dec 2018 NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a major new analysis of regulatory data reveals. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer 06 Jun 2018
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018
European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer 22 Nov 2017
ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 16 Nov 2017
Breakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs Fund 13 Oct 2017
ICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancers 20 Sep 2017